Search clinical trials for: Hematopoietic stem cell mobilization

Total 58567 results

M.D. Anderson Cancer Center
RUNX1 Foundation

Recruiting

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

RUNX1 Familial Platelet Disorder

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Acute Myeloid Leukemia | Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm | Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States
Zhongnan Hospital

Not yet recruiting

The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization

Granulocyte Colony-Stimulating Factor

China
Washington University School of Medicine
Biogen; BioLineRx, Ltd.

Recruiting

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Sickle Cell Disease

United States
The Affiliated People's Hospital of Ningbo University

Recruiting

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma

China
The Affiliated People's Hospital of Ningbo University

Recruiting

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Hematological Malignancy

China
Ning Huang

Not yet recruiting

A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF

Granulocyte Colony-stimulating Factor | Stem Cell Mobilization
City of Hope Medical Center

Recruiting

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO)

Sickle Cell Disease

United States
University of Chicago
National Cancer Institute (NCI)

Recruiting

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Hematologic Malignancy

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4-Positive | T-Lymphocytopenia

United States
BioLineRx, Ltd.

Active, not recruiting

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM (GENESIS)

Multiple Myeloma

United States, Spain, Hungary, Germany, Italy
Washington University School of Medicine
BioLineRx, Ltd.

Completed

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | Hodgkin's Disease | Hodgkins Disease

United States
Sandoz
Hexal AG

Active, not recruiting

Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors (SMART)

Hematopoietic Stem Cell Mobilization

Germany
Surbhi Sidana, MD

Completed

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Multiple Myeloma

United States
Emory University

No longer available

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Healthy

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult... and other conditions

United States
GPCR Therapeutics, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Multiple Myeloma | Non-hodgkin's Lymphoma | Hodgkin's Disease

United States
Julio Ramirez
University of Louisville

Terminated

Patients Response to Early Switch To Oral:Osteomyelitis Study (PRESTO:Osteo)

Osteomyelitis

United States
Sanofi
Genzyme, a Sanofi Company

Completed

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

Multiple Myeloma

Sweden, Estonia, Belgium, Lithuania
Dartmouth-Hitchcock Medical Center

Completed

Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

Hematologic Malignancies

United States
Kyowa Kirin Co., Ltd.

Completed

KRN125 for Mobilization of Hematopoietic Stem Cells

Peripheral Blood Stem Cell Transplantation

Japan
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Healthy Volunteers

United States
Massachusetts General Hospital
The Leukemia and Lymphoma Society

Completed

Meloxicam vs Placebo for Mobilization

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Hematopoietic Stem Cells

United States
Hongnan Mo

Unknown

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Hematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell Mobilization

China
M.D. Anderson Cancer Center
Proteonomix, Inc.

Completed

Plerixafor for Stem Cell Mobilization in Normal Donors

Blood And Marrow Transplantation

United States
Natural Immune Systems Inc

Unknown

Evaluation of Plant-based Nutritional Products on Stem Cells

Stem Cell Mobilization | Hematopoietic Stem Cell Mobilization | Stem Cell Homing

United States
University of California, San Francisco

Terminated

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

Severe Combined Immunodeficiency

United States
National Cancer Institute (NCI)

Completed

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Multiple Myeloma | Plasma Cell Myeloma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation

Healthy

United States
TriStar Health

Withdrawn

Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease.

Crohn's Disease
Alessandra Biffi

Completed

Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease

Sickle Cell Disease Without Crisis

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
GlaxoSmithKline

Completed

Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)

Transplantation, Stem Cell

United States
H. Lee Moffitt Cancer Center and Research Institute
ESP Pharma

Terminated

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

Acute Myeloid Leukemia (AML)

United States
Washington University School of Medicine

Completed

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Wang Guorong

Unknown

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Multiple Myeloma

China
Nationwide Children's Hospital

Withdrawn

Autologous Stem Cell Transplant for Refractory Crohn's Disease

Crohn's Disease
Memorial Sloan Kettering Cancer Center

Completed

Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

Beta Thalassemia Major | Congenital Anemias

United States
Asan Medical Center

Unknown

Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization

Multiple Myeloma

Korea, Republic of
Azienda Ospedaliera San Giovanni Battista

Unknown

Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment

Blood Diseases

Italy
New Mexico Cancer Care Alliance
Oxnard Foundation

Terminated

Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

Healthy Subjects

United States
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

Lymphoma

Japan
Polyphor Ltd.

Completed

Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

Healthy

Germany
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Multiple Myeloma

Japan
BioLineRx, Ltd.

Completed

A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers

Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)

Israel
University of Arkansas

Terminated

Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization

Multiple Myeloma

United States
University of Washington
National Heart, Lung, and Blood Institute (NHLBI); Genzyme, a Sanofi Company; George Papanicolaou Hospital

Completed

Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major

Beta-Thalassemia

Greece
University Hospital, Clermont-Ferrand

Completed

Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1)

Children Cancer, Solid Tumor

France

Search clinical trials for: Hematopoietic stem cell mobilization

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations